Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334789 · ClinicalTrials.gov registry record · Phase 1
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
A Phase 1 study of Adult Solid Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 5
- Study locations
NCT00334789 is a Phase 1 study of Adult Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants, above the 34-participant average among 9 other Adult Solid Neoplasm trials with a reported enrollment target (50% higher). The trial reports 5 study locations across 2 states.
The verdict
NCT00334789, a Phase 1 study of Adult Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors. Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells to look more like normal cells, and to grow and spread more slowly. Giving belinostat together with isotretinoin may be an effective treatment for metastatic or unresectable solid tumors.
Conditions Studied
Interventions
- DRUG Belinostat
- DRUG Isotretinoin
- OTHER Pharmacological Study
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
- USC / Norris Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
- City of Hope South Pasadena - South Pasadena
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-06-12 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334789
The ClinicalTrials.gov registry entry for NCT00334789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 9 other Adult Solid Neoplasm trials with a reported enrollment target (50% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Belinostat is the first listed.
NCT00334789 reports 5 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00334789 about?
NCT00334789 is a clinical study titled "Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery". This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors. Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes n...
What is the current status of trial NCT00334789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2006-06-12. Estimated completion is 2018-03-29.
What conditions does trial NCT00334789 study?
This clinical trial studies the following conditions: Adult Solid Neoplasm.
What interventions are being tested in trial NCT00334789?
The interventions under investigation include: Belinostat (DRUG), Isotretinoin (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00334789?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334789 being conducted?
This trial has 5 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.